Literature DB >> 24990314

Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

A Gupta1, W Fujita, I Gomes, E Bobeck, L A Devi.   

Abstract

BACKGROUND AND
PURPOSE: Opioid receptor function is modulated by post-activation events such as receptor endocytosis, recycling and/or degradation. While it is generally understood that the peptide ligand gets co-endocytosed with the receptor, relatively few studies have investigated the role of the endocytosed peptide and peptide processing enzymes in regulating receptor function. In this study, we focused on endothelin-converting enzyme 2 (ECE2), a member of the neprilysin family of metallopeptidases that exhibits an acidic pH optimum, localizes to an intracellular compartment and selectively processes neuropeptides including opioid peptides in vitro, and examined its role in modulating μ receptor recycling and resensitization. EXPERIMENTAL APPROACH: The effect of ECE2 inhibition on hydrolysis of the endocytosed peptide was examined using thin-layer chromatography and on μ opioid receptor trafficking using either elisa or microscopy. The effect of ECE2 inhibition on receptor signalling was measured using a cAMP assay and, in vivo, on antinociception induced by intrathecally administered opioids by the tail-flick assay. KEY
RESULTS: The highly selective ECE2 inhibitor, S136492, significantly impaired μ receptor recycling and signalling by only those ligands that are ECE2 substrates and this was seen both in heterologous cells and in cells endogenously co-expressing μ receptors with ECE2. We also found that ECE2 inhibition attenuated antinociception mediated only by opioid peptides that are ECE2 substrates. CONCLUSIONS AND IMPLICATIONS: These results suggest that ECE2, by selectively processing endogenous opioid peptides in the endocytic compartment, plays a role in modulating opioid receptor activity. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24990314      PMCID: PMC4292980          DOI: 10.1111/bph.12833

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  64 in total

1.  Recycling and resensitization of delta opioid receptors.

Authors:  N Trapaidze; I Gomes; M Bansinath; L A Devi
Journal:  DNA Cell Biol       Date:  2000-04       Impact factor: 3.311

2.  Opioid receptor oligomerization. Detection and functional characterization of interacting receptors.

Authors:  Ivone Gomes; Julija Filipovska; Lakshmi A Devi
Journal:  Methods Mol Med       Date:  2003

3.  Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.

Authors:  K Shirotani; S Tsubuki; N Iwata; Y Takaki; W Harigaya; K Maruyama; S Kiryu-Seo; H Kiyama; H Iwata; T Tomita; T Iwatsubo; T C Saido
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

4.  Peptidases prevent mu-opioid receptor internalization in dorsal horn neurons by endogenously released opioids.

Authors:  Bingbing Song; Juan Carlos G Marvizón
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

Review 5.  Acidification of the endocytic and exocytic pathways.

Authors:  I Mellman; R Fuchs; A Helenius
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

6.  Proenkephalin A-derived peptide E and its fragments alter opioid contractility in the small intestine.

Authors:  T P Davis; G L Hoyer; P Davis; T F Burks
Journal:  Eur J Pharmacol       Date:  1990-12-04       Impact factor: 4.432

7.  Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development.

Authors:  H Yanagisawa; R E Hammer; J A Richardson; N Emoto; S C Williams; S i Takeda; D E Clouthier; M Yanagisawa
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

8.  Optimisation and validation of an angiotensin-converting enzyme inhibition assay for the screening of bioactive peptides.

Authors:  Vanessa Vermeirssen; John Van Camp; Willy Verstraete
Journal:  J Biochem Biophys Methods       Date:  2002-03-04

9.  F11 neuroblastoma x DRG neuron hybrid cells express inhibitory mu- and delta-opioid receptors which increase voltage-dependent K+ currents upon activation.

Authors:  S F Fan; K F Shen; M A Scheideler; S M Crain
Journal:  Brain Res       Date:  1992-09-11       Impact factor: 3.252

10.  The preendosomal compartment comprises distinct coated and noncoated endocytic vesicle populations.

Authors:  S H Hansen; K Sandvig; B van Deurs
Journal:  J Cell Biol       Date:  1991-05       Impact factor: 10.539

View more
  13 in total

1.  Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity.

Authors:  Achla Gupta; Ivone Gomes; Erin N Bobeck; Amanda K Fakira; Nicholas P Massaro; Indrajeet Sharma; Adrien Cavé; Heidi E Hamm; Joseph Parello; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

2.  Delta opioid receptors recycle to the membrane after sorting to the degradation path.

Authors:  Iness Charfi; Khaled Abdallah; Louis Gendron; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2017-12-29       Impact factor: 9.261

Review 3.  Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions.

Authors:  Lloyd D Fricker; Elyssa B Margolis; Ivone Gomes; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2020-06-02       Impact factor: 4.436

4.  Agonist that activates the µ-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.

Authors:  Nestor Nivardo Jiménez-Vargas; Yang Yu; Dane D Jensen; Diana Daeun Bok; Matthew Wisdom; Rocco Latorre; Cintya Lopez; Josue O Jaramillo-Polanco; Claudius Degro; Mabel Guzman-Rodriguez; Quentin Tsang; Zachary Snow; Brian L Schmidt; David E Reed; Alan Edward Lomax; Kara Gross Margolis; Christoph Stein; Nigel W Bunnett; Stephen J Vanner
Journal:  Gut       Date:  2021-03-30       Impact factor: 23.059

5.  GPR83 engages endogenous peptides from two distinct precursors to elicit differential signaling.

Authors:  Seshat M Mack; Ivone Gomes; Amanda K Fakira; Mariana L Duarte; Achla Gupta; Lloyd Fricker; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2022-05-23       Impact factor: 4.054

6.  Opioid receptors signaling network.

Authors:  Lathika Gopalakrishnan; Oishi Chatterjee; Namitha Ravishankar; Sneha Suresh; Rajesh Raju; Anita Mahadevan; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2021-11-01       Impact factor: 5.908

7.  Protein Kinase D and Gβγ Subunits Mediate Agonist-evoked Translocation of Protease-activated Receptor-2 from the Golgi Apparatus to the Plasma Membrane.

Authors:  Dane D Jensen; Peishen Zhao; Nestor N Jimenez-Vargas; TinaMarie Lieu; Marina Gerges; Holly R Yeatman; Meritxell Canals; Stephen J Vanner; Daniel P Poole; Nigel W Bunnett
Journal:  J Biol Chem       Date:  2016-03-30       Impact factor: 5.157

8.  Identification of GPR83 as the receptor for the neuroendocrine peptide PEN.

Authors:  Ivone Gomes; Erin N Bobeck; Elyssa B Margolis; Achla Gupta; Salvador Sierra; Amanda K Fakira; Wakako Fujita; Timo D Müller; Anne Müller; Matthias H Tschöp; Gunnar Kleinau; Lloyd D Fricker; Lakshmi A Devi
Journal:  Sci Signal       Date:  2016-04-26       Impact factor: 8.192

Review 9.  Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Caroline Kerridge; Anthony J Turner
Journal:  Front Aging Neurosci       Date:  2014-09-17       Impact factor: 5.750

Review 10.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.